The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: The good the bad and the uncertain: A comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011

European Heart Journal

Volumn 35, Issue 15, 2014, Pages 960-968

  Ray, Kausik K ^a   Kastelein, John J P ^b   Matthijs Boekholdt, S ^b   Nicholls, Stephen J ^c   Khaw, Kay Tee ^d   Ballantyne, Christie M ^e   Catapano, Alberico L ^f   Reiner, Željko ^g   Lüscher, Thomas F ^h  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e BAYLOR UNIVERSITY   (United States)

^f UNIVERSITY OF MILAN   (Italy)

^g KBC Zagreb   (Croatia)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DYSLIPIDEMIA; EUROPE; HIGH RISK PATIENT; HUMAN; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SELF CARE; ADULT; ATHEROSCLEROSIS; BLOOD; DYSLIPIDEMIAS; EVIDENCE BASED MEDICINE; HEALTH; HYPERCHOLESTEROLEMIA; MEDICAL SOCIETY; PATIENT SELECTION; PRIMARY PREVENTION; PROCEDURES; RISK FACTOR; UNITED STATES;

ADULT; AMERICAN HEART ASSOCIATION; ATHEROSCLEROSIS; CHOLESTEROL, LDL; DYSLIPIDEMIAS; EUROPE; EVIDENCE-BASED MEDICINE; GLOBAL HEALTH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84898950294     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu107     Document Type: Article

References (19)

1. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, WilsonPW. 2013ACC/AHAGuideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 [Epub ahead of print].
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239
3. Reiner Z, Catapano AL, DeBacker G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818
4. Perk J, DeBacker G, Gohlke H, GrahamI, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-1701
5. Ridker PM, Cook NR. Statins: New American guidelines for prevention of cardiovascular disease. Lancet 2013;382:1762-1765
6. Reiner Z. Guidelines, position papers and critical reviews: Differences and similarities. Eur J Prev Cardiol 2013;20:3-5
7. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97: 1837-1847
8. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-3490
9. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-Analysis. JAMA 2012;307:1302-1309
10. Mora S, Buring JE, Ridker PM. Discordance of LDL cholesterol with alternative LDL-related measures and future coronary events. Circulation 2014;129:553-561
11. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can lowdensity lipoprotein be too low? The safety and efficacy of achieving very low lowdensity lipoprotein with intensive statin therapy: A PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411-1416
12. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H. Safety and efficacy of Atorvastatin-induced very low-Density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol 2007;100:747-752
13. De Backer G, Catapano AL, Chapman J, Graham I, Reiner Z, Perk J, Wiklund O. Guidelines on CVD prevention: Confusing or complementary? Atherosclerosis 2013;226:299-300
14. Reiner Z. New ESC/EAS Guidelines for the management of dyslipidaemias: Any controversies behind the consensuš Eur J Cardiovasc Prev Rehabil 2011;18:724-727
15. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson J, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW. 2013 ACC/AHA Guideline on the Assessment ofCardiovascular Risk:AReport of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation 2013 [Epub ahead of print].
16. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-952
17. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Reducing risk in heart disease: An expert guide to clinical practice for secondary prevention of coronary heart disease. Melbourne: National Heart Foundation of Australia, 2012
18. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012
19. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J Jr, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29:151-167